New guidelines for management of advanced prostate cancer

The American Urological Association (AUA), together with the American Society for Radiation Oncology (ASTRO) and the Society for Urologic Oncology (SUO), has just issued a new set of guidelines for the management of advanced prostate cancer (see here). … READ MORE …

Axumin-based PET/CT scans and detection of recurrent prostate cancer

A new report from a relatively small, single-institution study has provided additional information about the utility of [18F]fluciclovine (Axumin) PET/CT scans in the detection of recurrent prostate cancer after definitive first-line treatment. … READ MORE …

The definition of a SECOND biochemical recurrence (after prostatectomy AND salvage radiation)

There is no standard definition of SECOND biochemical (PSA-detected) recurrence (BCR); that is, recurrence after both prostatectomy and salvage radiation (SRT). … READ MORE …

Early data suggest 18F-DCFPyL PET/CT scans can change patient management

A media release issued yesterday by Progenics Pharmaceuticals states that the investigational imaging agent 18F-DCFPyL changed physician behavior in the management of biochemically recurrent prostate cancer in > 65 percent of patients. … READ MORE …

Does curcumin delay time to prostate cancer recurrence in men on IADT?

The results of a small, randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients already treated on intermittent androgen deprivation therapy (IADT) have recently been published. … READ MORE …

Whole pelvic salvage radiation + short-term ADT improves oncologic outcomes

We didn’t expect to see data from the SPPORT trial for another 2 years, but the research team hit their recruitment goal early and have already been able to provide 5-year results. … READ MORE …

Three-year biochemical recurrence after Retzius-sparing RALP

Back in January this year we commented on a technique known as Retzius-sparing radical prostatectomy, which — according to its advocates — is said to facilitate recovery of erectile function post-surgery. … READ MORE …

The accurate prognosis of recurrence- and metastasis-free survival

A company based on Northern Ireland called Almac Diagnostics has been working on the development of a 70-gene genetic assay (which they refer to as their Prostate Cancer Metastatic Assay) capable of projecting probability of metastasis-free survival in men treated for prostate cancer. … READ MORE …

Axumin PET/CT scans change treatment recommendations in recurrent prostate cancer

The value of many cancer-related tests is actually based on whether the results of the particular test change the way that  physicians plan to treat specific patients (hopefully for the better). … READ MORE …

INO-5150 in early treatment of biochemically recurrent prostate cancer

In 2015, Inovio Pharmaceuticals started a Phase I trial of INO-5150 — a new type of immunotherapy using a DNA vaccine for prostate cancer which targets both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA). … READ MORE …

Gallium-68 PSMA PET/CT scans changed management in 39 percent of patients

The gold standard for the clinical relevance of any new test in the management of a specific disease is … Do the results of the test change the way a physician would previously have managed patients? … READ MORE …

Radio-guided salvage surgery for recurrent prostate cancer

A recent article (in German in Der Urologe) has discussed the early use of PSMA-radio-guided surgery (PSMA-RGS) for targeted resection of localized prostate cancer recurrence. … READ MORE …

Physical activity and cancer recurrence: a detailed review

Readers with a strong interest in the relationships between exercise and risk for cancer recurrence may want to download and read the full text of a recent article by Friedenreich et al. … READ MORE …

What we have learned from radiolabeled choline PET/CT scanning to date

A newly published paper in the Journal of Urology provides additional data on the role of sophisticated, modern scanning methods in the management of men with recurrent prostate cancer after first-line surgical treatment. … READ MORE …

Is IL-33 expression a key to risk for prostate cancer progression and metastasis?

According to a newly published article in the journal Scientific Reports, men who lose normal expression of a protein known as interleukin-33 or IL-33 are at higher risk for recurrence of their prostate cancer within 5 years than men who do not lose the expression of this biomarker. … READ MORE …